Moderna Inc.
Moderna Updates 2025 Financial Performance and 2026 Outlook
Summary
Moderna, Inc. provided preliminary financial results for fiscal year 2025, expecting approximately $1.9 billion in revenue and $5.0 - $5.2 billion in GAAP operating expenses. The company also expects its cash balance to be around $8.1 billion at the end of 2025. Moderna anticipates up to 10% revenue growth in 2026, with further reductions in GAAP operating expenses. The company is also expecting potential approvals of its flu and flu/COVID combination vaccines in 2026, as well as pivotal trial data readouts in oncology, rare disease, and infectious disease.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement